The Clinical Study Of Depression In Parkinson's Disease

Objective Parkinson's Disease is one of the most common neurodegenerative disease with a tedious duration and difficult to cure. Recently, it was found that depression was common in Parkinson's disease and depression would have negative impact on the quality of daily living.Outcomes from the foreign clinical study noted that depression occurred in approximately half of PD patients and was the most significant predictive factor. Although lots of study were carried out, it remains controversial about its prevalence,clinical manifestation and related factors et al. The objective of this article is to estimate the prevalence of depression in Parkinson's Disease and the factors relatedto it; to find possible pathogenesis; then to assess clinical outcomes in patients with momoamine oxidase B inhibitor selegiline treatment through analyze the clinical data.Method The severity of PD was evaluated by Hoehn-Hahr stage and the motor function was evaluated by UPDRSIII score during on-phase, the level of depression was evaluated by HAMD-17 score. Stepwise multiple regression analysis and partial correlation analysis were carried out to test the association between the dependent variable HAMD-17 score and the independent variables including age, gender, duration, UPDRSIII score and H-Y stage. Otherwise, selegiline l0mg/d was administrated in 9 of 36 patients, 3 month later the UPDRSIII score and HAMD score were collected again. Result Depression occurred in 15 of all 36 patients and the total occurrence rate was 41.7%, 33.3% in men and 47.6% in womenrespectively(P< 0.07,).The most frequent items of HAMD are as follows: depressive emotion, decreased interest, slow, somatic and mental anxiety et al. The UPDRSIII score of depressed group was higher than that of non-depressed group (P< 0.07,). The occurrence rate of depression in 1.0-1.5 stage group, 2-2.5 stage group, 3 stage and above group were 10.0%, 47.1% and 66.7% respectively, there weresignificantly difference in three group(P<0.05). Through stepwise multiple regression analysis and partial correlation analysis, we found that long duration of PD and high score of UPDRSIII were associated with the level of depression while gender age and H-Y stage did not.In the group of 9 patients treated with selegiline, the UPDRSIII score and HAMD score both decreased significantly(P<0.001 vs P<0.05). Conclusion1. Depression is a very common symptom in PD.2. The most frequent depressive symptoms in PD are as follows: depressive emotion, decreased interest, slow, somatic and mental anxiety et al.3. In addition to the sociopsychological reaction to the disability, the occurrence of depression is mainly due to the underlying neurobiochemical and neuropathological changes.4. Selegiline can improve not only motor function but also the comorbided depression symptom in PD.